热门资讯> 正文

Cadrenal Therapeutics GAAP EPS of -$1.87

2025-08-12 02:08

Cadrenal Therapeutics press release (NASDAQ:CVKD): Q2 GAAP EPS of -$1.87.
On June 30, 2025, Cadrenal had cash and cash equivalents of $5.6 million, compared to $10.0 million as of December 31, 2024. The Company had approximately 2.0 million shares of common stock outstanding as of June 30, 2025.

More on Cadrenal Therapeutics

Seeking Alpha’s Quant Rating on Cadrenal Therapeutics
Historical earnings data for Cadrenal Therapeutics
Financial information for Cadrenal Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。